Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Put Hughes Syndrome on Your Radar

Graham R.V. Hughes, MD  |  Issue: April 2007  |  April 1, 2007

Sero-negative APS: I assume that all of us see patients with many of the hallmarks of APS, including arterial thrombosis, thrombocytopenia, valve lesions, recurrent pregnancy loss, and so on, in whom aPL tests remain doggedly negative. Explanations for this situation might include wrong diagnosis, a disappearance of antibodies over time, or simply that more aPL-related tests are needed. As a clinician, however, I believe that the concept of sero-negative APS is useful, just as sero-negative RA and sero-negative lupus were decades before.15

Anecdotes for the Clinically Curious

Neurological features of APS almost certainly embrace sleep disturbance. In my clinic, I have an extended family with both APS and autism, which may just be a clinical coincidence. Three of my patients have developed acute anosmia. Peripheral and autonomic nerve problems and cases of reflex dystrophy are also being described. As in diabetes, it may be that ischemia of peripheral nerves renders them more sensitive to external pressure. One of my APS patients with lumbar disc disease and severe symptoms of spinal stenosis and claudication improved once anticoagulation was started. Fatigue, as in lupus, is a frequent and major complaint, and often improves significantly once anticoagulation is started. More difficult to explain, but certainly a frequent observation, is the improvement in the arthralgia (in primary APS) with anticoagulants.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Table 1 (see below) gives a list of features which I believe are of help in diagnosis—certainly useful in the differentiation from other coagulopathies.

Treatment

The indications for aspirin (or clopidogrel), heparin, and warfarin are reviewed in detail elsewhere, and I will restrict this section to three specific comments.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

First, the use of a two- to three-week heparin trial in APS patients with severe frequent headache but with normal MRIs may be informative. Although a “soft” diagnostic tool with significant placebo input, in some patients the improvement or even abolition of headache and migraine with a course of self-administered heparin (e.g., Fragmin 10,000 units daily) gives some support to the difficult decision to move to warfarin.

Second, it is important to achieve a therapeutic INR with warfarin, ideally with a self-testing INR machine. There is probably no overall correct INR. Usually, arterial thrombosis appears to require a higher INR than venous. In neurology, however, we frequently see a higher INR requirement (e.g., 3.5–4), with the headaches, TIA, and memory impairment predictably returning when the INR falls below, for example, a precise reading of 3.4. For such patients, the use of self-testing machines is as important to a reasonably normal life as is self-measurement of insulin dose in some diabetics.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Antiphospholipid Antibody Syndrome (APS)AutoimmuneHughes SyndromePathogenesisTreatment

Related Articles

    APS: What Rheumatologists Should Know about Hughes Syndrome

    February 17, 2016

    The problem that dogs the work of all of those treating patients with antiphospholipid syndrome (APS) is the apparent lack of knowledge of the syndrome, both by the general public, as well as by swaths of the medical fraternity. Perhaps it was ever thus—a syndrome less than 40 years old could be described as new,…

    Antiphospholipid Antibody Testing Update

    January 13, 2012

    Successes, challenges, and controversies of diagnostic methods for APS

    Why Antiphospholipid Antibody Syndrome Should Be On Your Radar

    February 1, 2014

    With a wide range of clinical manifestations and frequent occurrence among rheumatology patients, APS is one for rheumatologists to watch

    Case Report: A Patient Presents with Digital Ischemia & Gangrene

    June 10, 2023

    Defined by the presence of antiphospholipid antibodies (aPL) in individuals with clinical evidence of thrombosis or pregnancy morbidity, antiphospholipid syndrome (APS) is a systemic autoimmune thrombophilia. Clinical thrombosis, which should be confirmed by objective validated criteria (e.g., imaging studies or histopathology), can occur in the arterial, venous or small vessel vasculature and is not limited…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences